Track topics on Twitter Track topics that are important to you
We list hundreds of Clinical Trials about "Sarah's Pastries and Candies" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.
We have published hundreds of Sarah's Pastries and Candies news stories on BioPortfolio along with dozens of Sarah's Pastries and Candies Clinical Trials and PubMed Articles about Sarah's Pastries and Candies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sarah's Pastries and Candies Companies in our database. You can also find out about relevant Sarah's Pastries and Candies Drugs and Medications on this site too.
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type,...
This study is for people whose cancer: - has resisted chemotherapy - are taking a break from chemotherapy - or are looking for an alternative to the toxic effects of chemotherapy The trial is looking to see if a very low carbohydrate diet can inhibit the growth of certain cancers. The two major goals of the RECHARGE study are to determine: - whether a very low carbohydrate diet can help participants reduce the amount of cancer in their b...
In this study, patients with metastatic HER2-negative breast cancer will receive treatment with ixabepilone and sorafenib until disease progression or unacceptable toxicity occurs. The Phase I portion of this study will determine the maximum tolerated doses (MTDs) of sorafenib and ixabepilone that may be used in combination for first- or second-line treatment of MBC. The MTDs identified in the Phase I portion of the study will be used in the Phase II portion which will evaluat...
Treatment of triple negative breast cancer (TNBC) relies heavily on different regimes of chemotherapeutic agents but remains one of the most challenging subtypes to treat because of the lack of specific therapies. Despite being sensitive to chemotherapy, many women with TNBC relapse quickly, developing locoregional recurrence or visceral metastasis. Toxicity and chemotherapy resistance are still major limitations in the treatment of patients with TNBC. Despite current trend of ...